DLX2 and gastric cancer: Our findings revealed that elevated DLX2 expression is correlated with poor prognosis and enhanced tumor proliferation, migration, invasion, and immune evasion, positioning DLX2 as both a prognostic biomarker and a potential therapeutic target in GC.